Purpose: To model juvenile-onset myopia progression as a function of race/ethnicity, age, sex, parental history of myopia, and time spent reading or in outdoor/sports activity. Methods: Subjects were 594 children in the Collaborative Longitudinal Evaluation of Ethnicity and Refractive Error (CLEERE) Study with at least three study visits: one visit with a spherical equivalent (SPHEQ) less myopic/more hyperopic than −0.75 diopter (D), the first visit with a SPHEQ of −0.75 D or more myopia (onset visit), and another after myopia onset. Myopia progression from the time of onset was modeled using cubic models as a function of age, race/ethnicity, and other covariates. Results: Younger children had faster progression of myopia; for example, the model-estimated 3-year progression in an Asian American child was −1.93 D when onset was at age 7 years compared with −1.43 D when onset was at age 10 years. Annual progression for girls was 0.093 D faster than for boys. Asian American children experienced statistically significantly faster myopia progression compared with Hispanic (estimated 3-year difference of −0.46 D), Black children (−0.88 D), and Native American children (−0.48 D), but with similar progression compared with White children (−0.19 D). Parental history of myopia, time spent reading, and time spent in outdoor/sports activity were not statistically significant factors in multivariate models. Conclusions: Younger age, female sex, and racial/ethnic group were the factors associated with faster myopic progression. This multivariate model can facilitate the planning of clinical trials for myopia control interventions by informing the prediction of myopia progression rates.

Decentralized ledgers that support rich applications suffer from three limitations. First, applications are provisioned tiny execution environments with limited running time, minimal stack size, and restrictive instruction sets. Second, applications must reveal their state transition, enabling miner frontrunning attacks and consensus instability. Third, applications offer weak guarantees of correctness and safety. We design, implement, and evaluate LEO, a new programming language designed for formally verified, zero-knowledge applications. LEO provisions a powerful execution environment that is not restricted in running time, stack size, or instruction sets. Besides offering application privacy and mitigating minerextractable value (MEV), LEO achieves two fundamental properties. First, applications are formally verified with respect to their high-level specification. Second, applications can be succinctly verified by anyone, regardless of the size of application. LEO is the first known programming language to introduce a testing framework, package registry, import resolver, remote compiler, formally defined language, and theorem prover for general-purpose, zero-knowledge applications.

Vision screenings are intended to efficiently identify students with possible visual impairment and initiate a referral for diagnosis and treatment. In many cases, at-risk students do not access the recommended care or experience delays in receiving care. The purpose of this article is to report the effect on adherence to vision screening recommendations by providing the eye examination at the students’ school and at no cost. Of the 1,306 students screened, 382 (29.2%) were identified with possible visual impairment. Parental consent for examination was obtained for 198 (51.8%) students. Our vision screening and examination program yielded similar adherence to follow-up as stand-alone vision screening programs. Future program considerations should address perceptual barriers that may be contributing to parental nonadherence to vision screening recommendations.

Dr. Raymond Chu is an associate professor at the Southern California College of Optometry at Marshall B. Ketchum University. Dr. Chu serves as clinical faculty in the Studt Center for Vision Therapy and Pediatric Optometry Services. He received his Doctor of Optometry degree from SUNY, State College of Optometry, and went on to complete a residency at the Southern California College of Optometry in pediatric optometry and vision therapy. Dr. Chu also holds a Master’s Degree in Instruction Design and Technology and is a fellow of the American Academy of Optometry.

Purpose We conducted a pilot randomized clinical trial of office-based active vision therapy for the treatment of childhood amblyopia to determine the feasibility of conducting a full-scale randomized clinical trial. Methods A training and certification program and manual of procedures were developed to certify therapists to administer a standardized vision therapy program in ophthalmology and optometry offices consisting of weekly visits for 16 weeks. Nineteen children, aged 7 to less than 13 years, with amblyopia (20/40–20/100) were randomly assigned to receive either 2 hours of daily patching with active vision therapy or 2 hours of daily patching with placebo vision therapy. Results Therapists in diverse practice settings were successfully trained and certified to perform standardized vision therapy in strict adherence with protocol. Subjects completed 85% of required weekly in-office vision therapy visits. Eligibility criteria based on age, visual acuity, and stereoacuity, designed to identify children able to complete a standardized vision therapy program and judged likely to benefit from this treatment, led to a high proportion of screened subjects being judged ineligible, resulting in insufficient recruitment. There were difficulties in retrieving adherence data for the computerized home therapy procedures. Conclusions This study demonstrated that a 16-week treatment trial of vision therapy was feasible with respect to maintaining protocol adherence; however, recruitment under the proposed eligibility criteria, necessitated by the standardized approach to vision therapy, was not successful. A randomized clinical trial of in-office vision therapy for the treatment of amblyopia would require broadening of the eligibility criteria and improved methods to gather objective data regarding the home therapy. A more flexible approach that customizes vision therapy based on subject age, visual acuity, and stereopsis might be required to allow enrollment of a broader group of subjects.

PURPOSE:To evaluate the psychometric properties of the original Parent and new Child Amblyopia Treatment Index (ATI), questionnaires that assess the burden of amblyopia treatment in children and families, and to compare scores between children treated with atropine or patching. METHODS:Parent ATI and Child ATI were administered to 233 children 7 to <13 years old and their parents as part of a randomized trial comparing patching and atropine for amblyopia treatment. For each ATI version, construct validity was assessed using factor analysis; internal consistency reliability was assessed using Cronbach's alpha. Data from the Parent ATI and Child ATI were correlated and scores for each version were compared between treatment groups. RESULTS:We analyzed the 3 subscales found in prior Parent ATI studies in younger children and confirmed subscales for adverse effects and treatment compliance, but not for social stigma, in both parent and child versions. Overall and subscale scores on the Parent ATI and Child ATI were moderately to well correlated except for the social stigma subscale. For both the Parent ATI and the Child ATI, children treated with atropine had better scores than those treated with patching, both overall and on treatment compliance and social stigma subscales (all p values ≤ 0.01). CONCLUSIONS:When used for children 7 to <13 years old, the Parent ATI and Child ATI have similar factor structures to each other and to the Parent ATI for children 3 to <7 years old. Atropine treatment was found to have less negative impact than patching.

OBJECTIVETo assess the stability of visual acuity improvement during the first year after cessation of amblyopia treatment other than spectacle wear in children aged 7 to 12 years.METHODSAt the completion of a multicenter randomized trial during which amblyopia treated with patching and atropine improved by at least 2 lines on the electronic Early Treatment of Diabetic Retinopathy Study testing protocol, 80 patients aged 7 to 12 years were followed up while not receiving treatment (other than spectacle wear) for 1 year.MAIN OUTCOME MEASURETen letters or more (> or =2 lines) worsening of visual acuity (measured using the electronic Early Treatment of Diabetic Retinopathy Study testing protocol) during the year following treatment discontinuation.RESULTSDuring the year following cessation of treatment, the cumulative probability of worsening visual acuity (> or =2 lines) was 7% (95% confidence interval, 3%-17%); 82% of patients maintained an increase in visual acuity of 10 letters or more compared with their visual acuity before starting treatment.CONCLUSIONVisual acuity improvement occurring during amblyopia treatment is sustained in most children aged 7 to 12 years for at least 1 year after discontinuing treatment other than spectacle wear.TRIAL REGISTRATIONClinicalTrials.gov identifier: NCT00094692.

PURPOSE: To assess the test-retest reliability of the electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity algorithm using the computerized Electronic Visual Acuity (EVA) tester in children 7 to < 13 years old.DESIGN: Test-retest reliability study.METHODS: This multicenter study involved 245 subjects at four clinical sites. As the main outcome measure, visual acuity was measured twice using the E-ETDRS testing protocol on the EVA system, which uses a programmed handheld device to communicate with a personal computer and a 17,inch monitor at a 3-m test distance.RESULTS: Test-retest reliability was high (r = .94 for right eyes and 0.96 for left eyes) and for both right and left eyes, 89% of retest scores were within 0.1 logarithm of the minimal angle of resolution (logMAR) (five let, ters) of the initial test score and 99% of retests were within 0.2 logMAR (10 letters). Reliability was high across the age range of 7 to <13 years. Based on 95% confidence level estimates, a change in visual acuity of 0.2 logMAR (10 letters) from a previous acuity measure is unlikely to result from measurement variability.CONCLUSIONS: The E-ETDRS protocol using the EVA has high test-retest reliability in children 7 to < 13 years of age. Potential advantages include better standardization across multiple sites, the ability to directly capture data electronically with an automatic acuity score calculation, the reduction of potential bias by limiting the tester's role, and the requirement of only a single testing distance for measurements from 20/800 to 20/12. This computerized testing method should be considered when visual acuity is used as an outcome measure in eye research involving children 7 to < 13 years old. (C) 2003 by Elsevier Inc. All rights reserved.

Saturday, December 14, 2002: Posters: Binocular Vision, Pediatric Optometry, Public Health, Vision Science: PDF Only

To compare patching and atropine as treatments for moderate amblyopia in children younger than 7 years.In a randomized clinical trial, 419 children younger than 7 years with amblyopia and visual acuity in the range of 20/40 to 20/100 were assigned to receive either patching or atropine at 47 clinical sites.Visual acuity in the amblyopic eye and sound eye after 6 months.Visual acuity in the amblyopic eye improved in both groups (improvement from baseline to 6 months was 3.16 lines in the patching group and 2.84 lines in the atropine group). Improvement was initially faster in the patching group, but after 6 months, the difference in visual acuity between treatment groups was small and clinically inconsequential (mean difference at 6 months, 0.034 logMAR units; 95% confidence interval, 0.005-0.064 logMAR units). The 6-month acuity was 20/30 or better in the amblyopic eye and/or improved from baseline by 3 or more lines in 79% of the patching group and 74% of the atropine group. Both treatments were well tolerated, although atropine had a slightly higher degree of acceptability on a parental questionnaire. More patients in the atropine group than in the patching group had reduced acuity in the sound eye at 6 months, but this did not persist with further follow-up.Atropine and patching produce improvement of similar magnitude, and both are appropriate modalities for the initial treatment of moderate amblyopia in children aged 3 to less than 7 years.

Sunday, December 9, 2001. Posters: Academy Information, Binocular Vision, Pediatric Optometry, Primary Care, Ocular Disease, Cornea and Contact Lenses: PDF Only

Sunday, December 9, 2001. Posters: Academy Information, Binocular Vision, Pediatric Optometry, Primary Care, Ocular Disease, Cornea and Contact Lenses: PDF Only